Histologic parameters does not predict short-term survival in severe alcoholic hepatitis by Dubois, Margaux
 
 
Unicentre 
CH-1015 Lausanne 
http://serval.unil.ch 
 
 
 
Year : 2020 
 
 
Histologic parameters does not predict short-term survival in 
severe alcoholic hepatitis 
 
Dubois Margaux 
 
 
 
 
 
 
Dubois Margaux, 2020, Histologic parameters does not predict short-term survival in 
severe alcoholic hepatitis 
 
Originally published at : Thesis, University of Lausanne 
 
Posted at the University of Lausanne Open Archive http://serval.unil.ch 
Document URN : urn:nbn:ch:serval-BIB_5D5ABDE5BB0A8 
 
 
Droits d’auteur 
L'Université de Lausanne attire expressément l'attention des utilisateurs sur le fait que tous les 
documents publiés dans l'Archive SERVAL sont protégés par le droit d'auteur, conformément à la 
loi fédérale sur le droit d'auteur et les droits voisins (LDA). A ce titre, il est indispensable d'obtenir 
le consentement préalable de l'auteur et/ou de l’éditeur avant toute utilisation d'une oeuvre ou 
d'une partie d'une oeuvre ne relevant pas d'une utilisation à des fins personnelles au sens de la 
LDA (art. 19, al. 1 lettre a). A défaut, tout contrevenant s'expose aux sanctions prévues par cette 
loi. Nous déclinons toute responsabilité en la matière. 
 
Copyright 
The University of Lausanne expressly draws the attention of users to the fact that all documents 
published in the SERVAL Archive are protected by copyright in accordance with federal law on 
copyright and similar rights (LDA). Accordingly it is indispensable to obtain prior consent from the 
author and/or publisher before any use of a work or part of a work for purposes other than 
personal use within the meaning of LDA (art. 19, para. 1 letter a). Failure to do so will expose 
offenders to the sanctions laid down by this law. We accept no liability in this respect. 
 
 
UNIVERSITE DE LAUSANNE - FACULTE DE BIOLOGIE ET DE MEDECINE 
Service de gastro-entérologie et d’hépatologie 
CHUV 
 
 
 
Histologic parameters does not predict short-term survival in severe 
alcoholic hepatitis 
 
 
 
THESE 
 
 
préparée sous la direction de la Professeure Christine Sempoux, 
avec la co-direction du Professeur Pierre Deltenre 
 
 
 
et présentée à la Faculté de biologie et de médecine de 
l’Université de Lausanne pour l’obtention du grade de 
 
 
 
DOCTEUR EN MEDECINE 
 
 
par 
 
 
Margaux Dubois 
 
 
 
Médecin diplômée de la Confédération Suisse  
Originaire Lausanne, (Vaud) 
 
 
 
Lausanne 
2020 
	

 
 
Valeur pronostic des paramètres histologiques de l’hépatite alcoolique 
 
Margaux Dubois, Amedeo Sciarra, Eric Trépo, Astrid Marot, Joan Saldarriaga, Christophe 
Moreno, Christine Sempoux, Pierre Deltenre 
 
Introduction : Le « alcoholic hepatitis histologic score » (AHHS) a été proposé comme un 
nouvel outil diagnostic pour déterminer la probabilité de décès dans les hépatites alcooliques 
aigues. Notre objectif est d’évaluer la valeur pronostic du AHHS. Matériel et méthode : Les 
biopsies du foie de patients avec une hépatite alcoolique sévère ont été analysées 
indépendamment par deux pathologues selon le AHHS. La fibrose hépatique a aussi été 
évaluée selon le score de Laennec. Résultats : Cent-sept patients ont été inclus, 89% ont reçu 
des corticostéroïdes. Le AHHS a été calculé chez 105 patients. La classification histologique 
a montré une atteinte légère, modérée et sévère selon AHHS dans 10, 29 et 66 des patients, 
respectivement. Une classification selon le score de Laennec était disponible chez 53 patients, 
parmi lesquels 49 avaient une cirrhose, 7 classifiés comme Laennec 4A, 15 4B, et 27 4C. Le 
taux de survie dans les groupes avec un score léger, modéré ou sévère du AHHS étaient de 
90%, 72% et 69% à 28 jours (p=0.6), 80%, 52% et 63% à 3 mois (p=0.3) et 70%, 41% et 58% 
à 6 mois (p=0.3), respectivement. Au sein du score AHHS, le paramètre de fibrose a démontré 
le meilleur accord interobserveur (kappa = 1.00). En comparant les patients avec une cirrhose 
Laennec 4B ou 4C, le taux de survie pour les patients sans cirrhose ou avec une cirrhose 
Laennec 4A était de 100% vs. 83% à 28 jours (p=0.16), 91% vs. 68% à 3 mois (p=0.13), et 
82% vs 64% à 6 mois (p=0.2), respectivement. En analyse multivariée, ajustée pour l’âge et le 
score de MELD, le AHHS et le score de Laennec n’étaient statistiquement pas significatifs 
d’un taux de mortalité à 6 mois. Conclusion : Le AHHS n’est pas prédictif d’une mortalité à 
court terme dans cette cohorte de patient avec un hépatite alcoolique sévère. 
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Histologic parameter score does not
predict short-term survival in severe
alcoholic hepatitis
Margaux Dubois1 , Amedeo Sciarra2, Eric Tr!epo3,4, Astrid Marot5,
Joan Saldarriaga2, Christophe Moreno3,4, Christine Sempoux2 and
Pierre Deltenre3,6
Abstract
Background and aim: The alcoholic hepatitis histologic score has been proposed as a new prognostic tool to
assess the risk of death in alcoholic hepatitis. We aimed to evaluate its prognostic value in patients with severe
alcoholic hepatitis.
Methods: Liver biopsies were analysed independently by two pathologists according to the alcoholic hepatitis
histologic score. The Laennec staging system was also used to evaluate fibrosis.
Results: One hundred and seven patients were included, and 89% of the patients received corticosteroids. The
alcoholic hepatitis histologic score was available in 105 patients. Histologic scoring showed mild, moderate and
severe scores in 10, 29 and 66 patients, respectively. Laennec staging was available for 53 patients, among whom 49
had cirrhosis, including 7 with Laennec 4A, 15 with 4B and 27 with 4C. Survival rates in mild, moderate and severe
alcoholic hepatitis histologic score groups were 90%, 72% and 69% at 28 days (p¼ 0.6), 80%, 52% and 63% at 3
months (p¼ 0.3), and 70%, 41% and 58% at 6 months (p¼ 0.3), respectively. Within the alcoholic hepatitis histo-
logic score, fibrosis demonstrated the best interobserver reproducibility (agreement¼ 100%, K¼ 1.00). Compared
to patients with Laennec 4B or 4C cirrhosis, survival rates for patients without cirrhosis or with Laennec 4A cirrhosis
were 100% vs 83% at 28 days (p¼ 0.16), 91% vs 68% at 3 months (p¼ 0.13), and 82% vs 64% at 6 months (p¼ 0.2),
respectively. In multivariate analysis adjusted for age and for model for end-stage liver disease score, the alcoholic
hepatitis histologic score and Laennec stage were not associated with 6-month mortality.
Conclusions: The alcoholic hepatitis histologic score is not predictive of short-term survival in this cohort of
patients with severe alcoholic hepatitis.
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Key summary
• The alcoholic hepatitis histologic score (AHHS) has been proposed as a prognostic tool to assess the risk of
death in alcoholic hepatitis. Validation of this score in independent cohort studies is required.
• In this study, AHHS did not correlate with 28-day, 3-month and 6-month survival.
• The Laennec staging system did not correlate with 6-month survival although there was a trend toward
increased survival among patients without cirrhosis and with Laennec 4A cirrhosis compared to those
with Laennec 4B and 4C disease.
• Further studies should evaluate whether the prognostic value of histologic parameters differs according to
the severity of the underlying alcoholic liver disease.
Introduction
Alcoholic hepatitis (AH) is a clinical syndrome corre-
sponding to clinical, biological and histological criteria.
It is characterised by recent onset of jaundice, with or
without other signs of liver decompensation (i.e. ascites
and/or encephalopathy), in patients with chronic alco-
hol abuse.1 Histologically, the presence of steatosis,
hepatocyte ballooning and an inflammatory infiltrate
with polymorphonuclear neutrophils are the criteria
required for the diagnosis of AH.1 Severe AH is defined
by a modified Maddrey’s discriminant function (mDF)
of 32 or higher2 and is the form of alcoholic liver dis-
ease that carries the poorest prognosis. Mortality rates
as high as 50% have been reported at 3 months without
treatment.3,4 As an accurate prediction of the risk of
death is required for patient care, several scores have
been developed to predict outcomes. In patients treated
with corticosteroids, the Lille score or the combination
of the Lille and the model for end-stage liver disease
(MELD) scores are widely used for helping physicians
to decide whether or not corticosteroids should be
maintained after 1 week of treatment according to the
probability of improvement in survival if corticoste-
roids are continued.5,6 However, the incidence of infec-
tions is increased during corticosteroid treatment, even
if administered for only a short period of time, with a
negative impact on patient prognosis.7 Thus, alterna-
tive predictive tools that are available at baseline are
warranted.
Although histologic confirmation of AH is not man-
datory in cases with typical presentation,8 the
European Association for the Study of the Liver
(EASL) guidelines recommend the use of histologic
analysis, as exclusive reliance on clinical criteria is asso-
ciated with a significant risk of misclassification.1
Recently, a new approach that focuses on histologic
parameters has been proposed for assessing outcomes
in AH patients. The alcoholic hepatitis histologic
score (AHHS) is a combination of four histologic fea-
tures (the presence of bridging fibrosis or cirrhosis,
hepatocellular or canalicular/ductular bilirubinostasis,
severe polymorphonuclear infiltration and
megamitochondria) that allows patient classification
into three groups with different risks of death within
90 days (3%, 19% and 51% in patients with favorable,
intermediate and poor scores, respectively).9 In addition
to this histologic score, developed for patients with AH,
the Laennec staging system has shown predictive value
for patients with cirrhosis.10,11 However, this score has
never been evaluated in the setting of AH.
In the present study, we aimed to assess the prog-
nostic value of the AHHS and of the Laennec staging
system for predicting survival at 28 days, 3 months and
6 months in two cohorts of consecutive patients with
AH seen in two tertiary centres.
Materials and methods
Patients
The study population was comprised of two cohorts.
First, all patients consecutively diagnosed with histo-
logic AH at the Lausanne University Hospital,
Lausanne, Switzerland between 2010–2017 were identi-
fied using a local prospective database of AH patients
and by reviewing the pathology reports from liver biop-
sies. To increase sample size, another prospective
cohort of patients diagnosed with AH at CUB
Hôpital Erasme, Brussels, Belgium was also included.
These patients were included in the derivation cohort
of a study aimed to establish a prognostic score com-
bining pre-treatment clinical variables and a molecular
signature in patients with AH.12
Transjugular biopsy specimens of the liver were
obtained from all patients (before corticosteroid thera-
py in those who were treated) and archived as formalin-
fixed, paraffin-embedded (FFPE) tissue blocks. To be
included in the present study, patients had histological-
ly confirmed AH and an mDF "32.2 Histologic criteria
included the presence of steatosis, ballooned hepato-
cytes and neutrophilic infiltration.1 Patients with viral
or autoimmune hepatitis, haemochromatosis or
co-infection with hepatitis A, B, C or E virus were
excluded. Patients were treated according to current
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guidelines. Corticosteroids were given orally (40 mg
prednisone for a maximum of 28 days) in the absence
of contraindication. Treatment was discontinued after
7 days in cases of non-response according to the Lille
model.6
Written informed consent was obtained from all indi-
viduals. The Ethics Committee of the Lausanne
University Hospital, Vaud canton, and the Ethics
Committee at CUB Hôpital Erasme approved the study.
Data collection
At inclusion, data collected included demographic data
(gender, age, height, weight), clinical data (alcohol con-
sumption and tobacco use, presence of ascites and
encephalopathy), past medical history (presence of
oesophageal varices, past alcohol use, presence of dia-
betes) and biological data (bilirubin, albumin, creati-
nine levels, prothrombin time or international
normalised ratio (INR), platelet count).
During follow-up, patients were followed as outpa-
tients every 6 months, or more frequently if required.
Data collected included clinical data (current alcohol
use) and data related to the development of complica-
tions of cirrhosis, or to the occurrence of liver trans-
plantation or death and causes of death.
Histopathological evaluation
Liver biopsies were fixed in formalin and embedded in
paraffin. Then, 3 lm slides were stained with
haematoxylin and eosin (H&E) and Masson’s tri-
chrome (Lausanne) or Sirius red (Brussels).
Histological parameters were independently analysed
by two liver pathologists. Discrepancies were resolved
by co-analysis at a multi-head microscope. All patients
were classified according to the AHHS score. The
presence of bridging fibrosis or cirrhosis, type of
bilirubinostasis, presence of severe polymorphonuclear
infiltration and presence of megamitochondria (defined
as small round eosinophilic structures in the cytoplasm
of hepatocytes) were assessed to classify patients into
mild (0–3 points), moderate (4–5 points) or severe (6–9
points) AHHS, as described by Altamirano et al.9
(Figure 1). Patients with cirrhosis were also classified
according to the Laennec staging system.10 This classi-
fication is based on the thickness of the fibrous septa
and the size of the nodules: A, mostly thin septa and
large nodules; B, at least two broad septa and <50% of
minute nodules; C, at least one very broad septum and
>50% of minute nodules.
Endpoints
The primary endpoint was overall survival at 6 months.
Secondary endpoints were survival at 28 days and at
3 months.
Statistical analysis
Inter-group differences for continuous and categorical
variables were tested using the Wilcoxon rank-sum test
(a) (b)
(c) (d)
Figure 1. Histological parameters of the alcoholic hepatitis histologic score (AHHS) and the Laennec staging system.
(a) Cirrhosis (Laennec 4C), Masson’s trichrome, original magnification X25. (b) Hepatocellular and canalicular bilirubinostasis,
haematoxylin and eosin, original magnification X100. (c) Megamitochondria (arrows), haematoxylin and eosin, original
magnification X400. (d) Severe polymorphonuclear infiltration, haematoxylin and eosin, original magnification X200.
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and Fisher’s exact test, respectively. Follow-up time
was defined as the period from the first day of initiation
of therapy or the day of liver biopsy to 6 months after
inclusion. Data for patients who had not died, includ-
ing those lost to follow-up, were censored at the date of
the last follow-up visit. Patients who underwent liver
transplantation were censored at the time of transplant.
Histopathological interobserver agreement was deter-
mined using the kappa (K) coefficient. Area under
receiver operating characteristic (AUROC) curve anal-
yses were used to compare the prognostic value of the
AHHS to the other prognostic scores. Univariable and
multivariable Cox regression proportional hazard
models were used to identify factors associated with
death. Hazard ratios (HRs) are reported with their
95% confidence intervals (CIs). To avoid bias related
to the effect of collinearity, when Child-Pugh or
MELD scores were included in multivariable analysis,
their constituent variables were not considered. A two-
tailed p< 0.05 was considered statistically significant.
All data analyses were performed using NCSS 2016
software (NCSS, Kaysville, Utah, USA).
Results
Patients
Sixty-five patients were identified at the Lausanne
University Hospital. Ten patients were excluded for
the following reasons: four had mDF <32, one had a
missing mDF, four had detectable hepatitis C virus
RNA, and one had acute hepatitis A virus infection.
Thus, 55 consecutive patients were included. Fifty-two
patients were included at CUB Hôpital Erasme. All
patients had mDF "32, none had hepatitis virus infec-
tion. Thus, the whole study population was made up of
107 patients. All patients were chronic alcohol consum-
ers (>60 g/day for males and >40 g/day for females),
had recent (<90 days) onset of jaundice (bilirubin level
>50 mmol/l), and less than 60 days of abstinence before
the onset of jaundice.
Demographics, clinical, and biological data for
included patients are summarised in Table 1. Results
are provided for patients included at Lausanne, for
those included at Brussels, and for the whole study
population. Overall, the median age was 54 years
(95% CI: 52–56) and 62% of patients were male. The
mean mDF at the time of liver biopsy was 62 (95% CI:
56–67). Histologic scoring according to the AHHS was
available for 53 patients included at Lausanne and for
all patients included at Brussels (Table 2). The median
AHHS was 7 (95% CI: 6–7). Ten patients (9%)
had AHHS mild disease, 29 patients (28%) had a mod-
erate AHHS, and 66 patients (63%) had a severe
AHHS. Histologic scoring according to the Laennec
staging system was available for 53 patients included
in Lausanne. For patients included in Brussels, classi-
fication according to the Laennec scoring system was
not feasible as it required new cutting of liver biopsies
to perform Masson’s trichrome staining which was,
unfortunately, not possible due to insufficient remain-
ing histological material. Among patients included at
Lausanne, 49 patients (92%) had cirrhosis. Seven
patients (14%) had Laennec 4A disease, 15 patients
(31%) had Laennec 4B disease and 27 patients (55%)
had Laennec 4C cirrhosis.
Table 1. Characteristics of patients at inclusion.
Characteristics
Cohort 1
(n¼ 55)
Cohort 2
(n¼ 52)
Overall
(n¼ 107) p Value
Age (years)a 54 (50–56) 54 (50–58) 54 (52–56) 0.8
Male sex (n, %) 35 (64%) 31 (60%) 66 (62%) 0.7
Aspartate aminotransferase (UI/l)a 125 (106–147) NA NA –
Alanine aminotransferase (UI/l)a 42 (38–49) NA NA –
Serum bilirubin (mmol/l)a 221 (148–273) 248 (157–342) 238 (188–276) 0.2
Serum albumin (g/l)a 27 (26–28) 27 (25–28) 27 (26–28) 0.5
Serum creatinine (mmol/l)a 72 (63–81) 71 (62–80) 71 (63–78) 0.9
INRa 1.7 (1.5–1.8) 1.8 (1.7–2.0) 1.7 (1.7–1.8) 0.003
MELD scorea 22 (20–23) 24 (21–26) 23 (21–24) 0.01
Child-Pugh scorea 10 (10–11) 11 (10–12) 10 (10–11) 0.005
mDFa 66 (59–73) 56 (48–64) 62 (56–67) 0.2
ABIC scorea 8.1 (7.5–8.7) 8.9 (7.9–9.2) 8.4 (8.1–8.8) 0.03
Corticosteroid therapy (n, %) 43 (78%) 52 (100%) 95 (89%) <0.001
Lille scorea 0.32 (0.18–0.42)b 0.32 (0.17–0.49) 0.32 (0.21–0.43) 0.9
Responders according to the Lille score (n, %) 28 (68%)b 22 (58%) 58 (62%) 0.4
ABIC: age, bilirubin, INR, creatinine; AHHS: alcoholic hepatitis histologic score; CI: confidence interval; INR: international normalised ratio; mDF:
modified Maddrey discriminant function; MELD: model for end-stage liver disease; NA: not available.
aData are expressed as median (95% CI); bavailable in 41 patients.
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Overall, 61 patients (57%) died. Among patients at
Lausanne who died (n¼ 24) the cause of death was
liver failure in 21 patients (88%), hepatocellular carci-
noma in one patient (4%), and was unknown for two
patients (8%). Two patients (4%) were lost to follow-
up at 6 months. One patient (2%) underwent liver
transplantation 3 years after inclusion. Among patients
included at Brussels, all deaths (n¼ 37) were liver-
related. One patient (2%) was lost to follow-up at
6 months. Seven patients (13%) underwent liver trans-
plantation, five patients (10%) within the first 6 months
for non-response to corticosteroids, one patient (2%)
at 7 months and one patient (2%) at 3 years after inclu-
sion. In the whole study population, the 28-day,
3-month and 6-month survival rates were 78% (95%
CI: 71–86), 62% (95% CI: 53–72), and 56% (95% CI:
46–65), respectively.
Ninety-five (89%) patients were treated with cortico-
steroids. Of these, 58 (62%) responded to therapy
according to the Lille score, categorised according to
the 0.45 cut-off. Patients who did not receive cortico-
steroids either had spontaneous improvement of liver
function tests or had infection that contraindicated cor-
ticosteroid therapy. In patients who received cortico-
steroids, survival rates at 6 months were better in those
who were responders according to the Lille score
than in those who were not responders (66% (95%
CI: 53–78) vs 34% (95% CI: 19–50), p< 0.001).
Alcohol intake during follow-up was available for
51 patients included at Lausanne. Among these
patients, 31 (61%) returned to alcohol consumption.
Abstainers had better survival rates at 6 months than
consumers (90% (95% CI: 77–100) vs 55% (95% CI:
37–72), p¼ 0.01).
Prognostic value of the AHHS and the Laennec
staging system
Survival rates in the mild, moderate and severe AHHS
groups were 90% (95% CI: 71–100), 72% (95% CI:
56–89) and 69% (95% CI: 79–89) at 28 days
(p¼ 0.6), 80% (95% CI: 55–100), 52% (95% CI: 34–
70) and 63% (95% CI: 51–75) at 3 months (p¼ 0.3),
and 70% (95% CI: 42–98), 41% (95% CI: 23–59) and
58% (95% CI: 46–70) at 6 months (p¼ 0.3), respective-
ly (Figure 2). Using other cut-offs for dichotomization
of the AHHS did not provide better results for predict-
ing survival (data not shown). Among the components
of the AHHS, severe polymorphonuclear infiltration
was the only variable predicting 6-month survival
(41% vs 63% for patients with and without severe
polymorphonuclear infiltration, p¼ 0.01), while other
parameters were not associated with survival.
Table 2. Histologic parameters of the study population.
Cohort 1
(n¼ 53)
Cohort 2
(n¼ 52)
Whole cohort
(n¼ 105) p Value
AHHS
Stage of fibrosis
No fibrosis, portal fibrosis, extensive fibrosis (n, %) 3 (6%) 4 (8%) 7 (7%) 0.7
Bridging fibrosis or cirrhosis (n, %) 50 (94%) 48 (92%) 98 (93%)
Bilirubinostasis
No or hepatocellular only (n, %) 26 (49%) 31 (60%) 57 (54%) 0.5
Canalicular or ductular (n, %) 11 (21%) 9 (17%) 20 (19%)
Canalicular or ductular plus hepatocellular (n, %) 16 (30%) 12 (23%) 58 (27%)
Polymorphonuclear infiltration
No or mild (n, %) 38 (72%) 29 (56%) 67 (64%) 0.11
Severe (n, %) 15 (28%) 23 (44%) 38 (36%)
Megamitochondria
No megamitochondria (n, %) 43 (81%) 34 (65%) 77 (73%) 0.08
Megamitochondria (n, %) 10 (19%) 18 (35%) 28 (27%)
AHHS categories
Mild (0–3) (n, %) 3 (6%) 7 (13%) 10 (9%) 0.06
Moderate (4–5) (n, %) 11 (21%) 18 (35%) 29 (28%)
Severe (6–9) (n, %) 39 (74%) 27 (52%) 66 (63%)
Laennec staging system
4A (n, %) 7 (14%) NA NA –
4B (n, %) 15 (31%) NA NA
4C (n, %) 27 (55%) NA NA
AHHS: alcoholic hepatitis histologic score; NA: not available.
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The AHHS did not predict response to corticoste-
roids defined with the Lille score using a 0.45 cut-off.
Response rates were 50%, 73% and 58% in the mild,
moderate and severe AHHS groups, respectively
(p¼ 0.3).
The AUROC curve of AHHS for 6-month survival
was 0.46 (95% CI: 0.34–0.56), lower than that of the
Child-Pugh score (0.71), the MELD score (0.75) and
the age, bilirubin, INR, creatinine score (ABIC) score
(0.73) (p value for all comparisons #0.001), and similar
to that of the mDF (0.50) (p¼ 0.24). In patients treated
with corticosteroids the AUROC curve of AHHS for 6-
month survival was lower than that of the Lille score
(0.69) (p¼ 0.001).
Interobserver agreement was assessed in patients
included at Lausanne. It was the best for fibrosis
(agreement¼ 100%, K¼ 1.00). Other K values were
84% (K¼ 0.74) for bilirubinostasis, 96% (K¼ 0.9)
for polymorphonuclear infiltration and 84%
(K¼ 0.46) for megamitochondria. Overall AHHS had
a 76% agreement rate with a K coefficient of 0.67.
With regard to the Laennec staging system, we con-
sidered patients without cirrhosis and with Laennec 4A
cirrhosis together to avoid comparison of too many
groups in the study population. Compared to patients
with Laennec 4B or 4C cirrhosis, survival rates of
patients without cirrhosis or with Laennec 4A cirrhosis
were 100% vs 83% (95% CI: 72–95) at 28 days
(p¼ 0.16), 91% (95% CI: 74–100) vs 68% (95% CI: 54–
83) at 3 months (p¼ 0.13) and 82% (95% CI: 59–100)
vs 64% (95% CI: 49–78) at 6 months (p¼ 0.2), respec-
tively (Figure 3).
At univariable analysis, the AHHS and the Laennec
staging system were not associated with the risk of
death at 6 months (Table 3). In multivariate analysis
adjusted for age and MELD score, the AHHS was not
associated with 6-month mortality (HR: 0.94, 95% CI:
0.80–1.10, p¼ 0.4) (Table 3, all patients, multivariable
model 1). When considering the Laennec system
instead of AHHS, the presence of Laennec 4B or 4C
cirrhosis was not associated with increased mortality at
6 months (HR: 4.31, 95% CI: 0.56–32.97, p¼ 0.16)
(Table 3, all patients, multivariable model 2). In mul-
tivariate analysis including only patients treated with
corticosteroids, the AHHS and the presence of Laennec
4B to 4C cirrhosis were not associated with 6-month
mortality (Table 3, patients treated with corticoste-
roids, multivariable models 1 and 2).
Discussion
In patients with AH, the most commonly used prog-
nostic scores require a 1-week course of corticosteroid
therapy to be calculated. Assessment of prognosis at
baseline would avoid exposure to corticosteroids
which increases the risk of infection, one of the most
frequent causes of mortality in patients with severe
AH, even if given for only a short period of time.
Several attempts have been made to develop scores
that provide pretreatment prognostic assessment,
including recent studies focusing on genes extracted
from a liver biopsy12,13 as well as older studies based
on histologic findings.14–17 The last histologic approach
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Figure 3. Survival curves according to the Laennec staging
system. CI: confidence interval; Mo: months.
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was proposed by Altamirano et al. who developed the
AHHS, a score based on four parameters, the combi-
nation of which allows classification of patients into
groups with mild, intermediate or severe histologic
AH.9 In the initial publication, the AHHS was strongly
associated with the probability of survival at 3 months.
However, validation of this score in independent
cohort studies is required before it becomes widely
applied. To date, two studies have aimed to validate
this score.18,19 In the first study, the AHHS was asso-
ciated with 90-day mortality, but this study included a
very limited number of patients. In the other study, no
predictive value of the AHHS was found.19 Another
study that focused on the interobserver variability in
scoring the four histologic parameters, observed signif-
icant interobserver variability among pathologists, lim-
iting the usefulness of the score in clinical practice.20
Hence, the present study was needed to provide addi-
tional data on the utility of this score for patient
prognostication.
The main finding of this study is that the AHHS was
not correlated with survival at 28 days, 3 months or 6
months. The main explanation for this unexpected
finding is likely related to the fact that only a limited
number of patients belonged to the low-risk group
according to the AHHS. This finding was previously
observed in a population of patients with severe AH in
which cirrhosis is a common finding.21 Indeed, the
presence of cirrhosis, or even of extensive fibrosis,
immediately adds three points to the AHHS classifica-
tion and any additional points will move a patient into
the intermediate severity group. Thus, the population
of patients we studied may have had a more severe
underlying liver disease than the population in the
Altamirano et al. study, a point further supported by
the fact that all patients had an mDF"32 and by the
observation of higher MELD and Lille scores in our
study population. Similarly, fewer patients received
corticosteroids in the Altamirano et al. study compared
to our study (45% vs 89%, respectively). Finally, death
rates at 3 months were lower in the Altamirano et al.
study than in ours (29% vs 38%, respectively).
Altogether, these findings indicate that the AHHS
may be more suitable for prognostic assessment in
patients with less severe AH than in a population
such as the one included in our study. However, this
hypothesis should be assessed in studies specifically
designed to investigate this point. Another point is
related to the fact that, currently, we lack factors able
to select which patients should undergo treatment.
Although our study was not designed to answer this
question, it did not suggest a role for histologic factors
in selecting which patients should be treated for AH.
This point deserves additional attention in future pro-
spective studies.
The second important finding of the present study is
the absence of discriminative prognostic information
between intermediate and severe AH according to the
AHHS. In addition, the interobserver reproducibility
of the AHHS was not perfect, especially for the criteria
related to the presence of megamitochondria, a point
that was already observed in the Altamirano et al.
study9 and by others.20 In contrast, the extent of fibro-
sis demonstrated 100% interobserver reproducibility.
Of note, the Laennec staging system, which is based
only on the extent of fibrosis, did not correlate with
6-month survival, although there was a trend toward
increased survival among patients without cirrhosis
and with Laennec 4A cirrhosis compared to those
with Laennec 4B and 4C. Taken together, these find-
ings may indicate that, if histologic factors are helpful
for predicting patient outcomes, their prognostic utility
would likely be driven by the extent of fibrosis, a find-
ing already observed in AH17,22 and established for
other liver diseases including non-alcoholic fatty liver
disease.11,23 This observation was expected as the
extent of liver fibrosis is correlated to the degree of
portal hypertension and related complications.24–26
We acknowledge that this study has potential limi-
tations including its limited sample size. However,
severe AH remains a rare complication among heavy
drinkers.3,27 In addition, this study included a similar
number of patients to the Altamirano et al. study, when
compared to either the derivation cohort (n¼ 96) or to
the validation cohort (n¼ 109). Hence, an effect size
similar to that observed in the Altamirano et al.
study should have been detected in our study popula-
tion. Another limitation was that, for patients included
at CUB Hôpital Erasme, classification according to the
Laennec scoring system was not possible. On the other
hand, our study has several strengths including the
inclusion of two cohorts of consecutive patients with
severe AH in two academic centres and the indepen-
dent evaluation of all biopsies by two pathologists with
expertise in liver disease.
In conclusion, the AHHS is not predictive of short-
term survival in this cohort of patients with severe AH.
Further studies should evaluate whether the prognostic
value of histologic parameters differs according to the
severity of liver disease.
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